HDAC6 and ovarian cancer: Decreased cell viability with this HDAC6 targeting PROTAC was previously shown to result from targeted degradation of IKAROS family zinc finger (IKZF) proteins at micromolar doses, although we did not measure any significant expression of IKZF1 and IKZF2 in ovarian cancers (Figure S5).